Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | PDE6D | O43924 | 1/20 | 0.56 |
| ▸ | PDE8A | O60658 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | PDE9A | O76083 | 1/20 | 0.56 |
| ▸ | PDE8B | O95263 | 1/20 | 0.56 |
| ▸ | PDE6A | P16499 | 1/20 | 0.56 |
| ▸ | PDE6G | P18545 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE6B | P35913 | 1/20 | 0.56 |
| ▸ | PDE6C | P51160 | 1/20 | 0.56 |
| ▸ | PDE1A | P54750 | 1/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.56 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.56 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818529 | 0.74 | PDE2A (0.69) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL30273078 | 0.74 | PDE2A (0.69) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL30273088 | 0.74 | PDE3B (0.51) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL9414983 | 0.74 | PDE3B (0.51) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL8506743 | 0.73 | PDE3B (0.48) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL6081699 | 0.73 | CDK4 (0.51) | PARP1MEN1KMT2A | |
| SCHEMBL8797538 | 0.72 | PDE2A (0.47) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL8796988 | 0.72 | PDE2A (0.47) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7269656 | 0.72 | PDE2A (1.00) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL1388122 | 0.70 | PDE3B (0.45) | PDE2APDE6DPDE8APDE5APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | disclosed |
| WO-1997025329-A1 | 5H,10H-IMIDAZO[1,2-a]INDOLO[3,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1997-07-17 | — | — | WO | disclosed |
| EP-0708778-B1 | IMIDAZO[1,2-A]PYRAZIN-4-ONE DERIVATIVES FOR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | RHONE POULENC RORER SA (FR) | 1997-02-05 | — | — | EP | disclosed |
| EP-0708778-A1 | IMIDAZO[1,2-A]PYRAZIN-4-ONE DERIVATIVES FOR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | RHONE POULENC RORER SA (FR) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002602-A1 | IMIDAZO(1,2-A)PYRAZIN-4-ONE DERIVATIVES FOR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | RHONE-POULENC RORER S.A. (FR) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | PDE2A 3935/4885PDE6D 4131/4885PDE8A 2879/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | PDE2A 3887/4885PDE6D 3681/4885PDE8A 3974/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | PDE2A 4097/4885PDE6D 4235/4885PDE8A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.